Displaying 32 (all) recruiting clinical trials.
-
A Phase 1 Study of RGX-104 a Small Molecule LXR Agonist as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
The purpose of the study is to look at RGX-104 as a single agent, and separately, in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus ...Phase
Interventional
-
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ...Phase
Interventional
-
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
The purpose of this study is to understand whether potential new drugs, AB680 and AB122, can be safely given to patients with pancreatic cancer in ...Phase
Interventional
-
A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL) and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
The purpose of this study is to look at how your body tolerates ME-401, how effective ME-401 may be, and how ME-401 is taken up ...Phase
Interventional
-
Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC
The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With ...Phase
Interventional
-
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination ...Phase
Interventional
-
An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease
The purpose of the study is to determine the safety and tolerability of the investigational product CYAD-211 when administered as a single infusion after a ...Phase
Interventional
-
A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
The purpose of the study is to determine the safety and tolerability of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every ...Phase
Interventional
-
A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-95251 A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRPa ALONE AND IN COMBINATION WITH CETUXIMAB OR RITUXIMAB IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS
The purpose of the study is to look at how your body tolerates CC-95251 and safety of the CC-95251 when administered intravenously (IV) as single ...Phase
Interventional
-
A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
The purpose of the study is to evaluate how your body tolerates IGM-2323, the safety of IGM-2323, and how IGM-2323 is taken up by your ...Phase
Interventional
